Core Viewpoint - Guangzheng Eye Hospital (002524.SZ) announced that its wholly-owned subsidiary, Shanghai Guangzheng New Vision Eye Hospital Investment Co., Ltd., plans to increase its investment in its wholly-owned subsidiary, Chengdu New Vision Eye Hospital Co., Ltd., by 30 million yuan, raising Chengdu New Vision's registered capital to 40 million yuan. After the capital increase, the company's ownership stake in the subsidiary remains at 100% [1] Group 1 - The investment amount for the capital increase is 30 million yuan [1] - The registered capital of Chengdu New Vision Eye Hospital will be 40 million yuan after the increase [1] - The company maintains a 100% ownership stake in Chengdu New Vision after the capital increase [1]

Core Viewpoint - The company plans to increase the registered capital of its subsidiary Chengdu New Vision Eye Hospital by 30 million yuan, raising it from 10 million yuan to 40 million yuan, using its own funds [1] Group 1: Investment Details - The investment will be made by Shanghai Guangzheng New Vision Eye Hospital Investment Co., Ltd., a wholly-owned subsidiary of the company [1] - After the capital increase, the company will continue to hold 100% equity in Chengdu New Vision, with no change in shareholding ratio [1] - The funding for this capital increase comes from the company's own funds, and it does not constitute a related party transaction or a major asset restructuring [1]

Group 1 - The company Guangzheng Eye Hospital announced the convening of its sixth board meeting on February 12, 2026, to review documents including a proposal for capital increase in its wholly-owned subsidiary [1] - Investors Ge Weidong and Fang Wenyuan have jointly invested 1 billion yuan each in Jianghuai, leading to a significant increase in the company's stock price [1] - Historical analysis indicates that retail investors participating in private placements have experienced both gains and losses [1]

Core Viewpoint - Guangzheng Eye Hospital (002524.SZ) announced that its wholly-owned subsidiary, Shanghai Guangzheng New Vision Eye Hospital Investment Co., Ltd., plans to increase its investment in its wholly-owned subsidiary, Chengdu New Vision Eye Hospital Co., Ltd., by 30 million yuan, raising Chengdu New Vision's registered capital to 40 million yuan. After the capital increase, the company's ownership stake in the subsidiary remains at 100% [1]. Group 1 - Guangzheng Eye Hospital's subsidiary, Shanghai Guangzheng New Vision, is set to invest 30 million yuan in Chengdu New Vision Eye Hospital [1]. - Following the capital increase, the registered capital of Chengdu New Vision will be 40 million yuan [1]. - The company will maintain a 100% ownership stake in Chengdu New Vision after the investment [1].

Group 1: Shareholder Pledge and Control - The controlling shareholder, Guangzheng Investment, has had 9.15 million shares frozen, accounting for 7.08% of its holdings and 1.78% of the company's total share capital. The freeze period is from January 30, 2026, to January 29, 2029. The company states this will not lead to a change in control and will not have a substantial impact on operations [2]. Group 2: Financial Performance - The company expects a net profit attributable to shareholders for 2025 to be between -5 million and -3 million yuan, indicating a significant reduction in losses of 97.14% to 98.28% compared to a loss of 175 million yuan in the same period of 2024. This improvement is attributed to lean operations in the medical sector, cost control, and a significant reduction in goodwill impairment [3]. Group 3: Related Party Transactions - The company’s board approved a total of up to 15 million yuan for daily related party transactions with Guangzheng Yanyuan Health Management Co., Ltd. and its subsidiaries for the year 2026 [4]. Group 4: Management Changes - A new senior management team has been appointed, including positions such as Vice President, Chief Financial Officer, and Board Secretary, as of December 28, 2025 [5]. Group 5: Business Development - The company has increased its investment in ophthalmology by acquiring, establishing, and holding stakes in multiple ophthalmology-related companies throughout 2025 [6].

Core Viewpoint - He Eye Hospital's refractive business is projected to achieve revenue of 135 million yuan in the first half of 2025, reflecting a year-on-year growth of 3.26%, indicating a return to a growth trajectory [1] Group 1: Business Performance - The refractive surgery average selling price (ASP) is on the rise due to an increased proportion of high-value procedures such as femtosecond laser and ICL crystal implantation [1]

Core Viewpoint - He Eye Hospital is implementing a regional development strategy focused on "deepening in Liaoning, radiating nationwide, hierarchical layout, and precise expansion" to build a national three-tier eye health medical service network [1] Group 1: Strategic Focus - The company is concentrating on key urban clusters such as Beijing-Tianjin-Hebei, Chengdu-Chongqing, the Greater Bay Area, and the Yangtze River Delta [1] - The operational model combines direct hospitals with optical franchise collaboration [1]

Group 1: Strategic Planning and Regional Development - The company focuses on a regional development strategy of "deepening in Liaoning, radiating nationwide, hierarchical layout, and precise expansion," targeting core urban clusters such as Beijing-Tianjin-Hebei, Chengdu-Chongqing, Greater Bay Area, and Yangtze River Delta [2][3] - Liaoning serves as the core base and profit pillar, maintaining stable operations and good cash flow, while expanding into provinces like Beijing, Chongqing, Chengdu, and Hainan [3] - The company is optimizing operations by closing underperforming units to enhance overall efficiency without affecting the national layout [3] Group 2: Business Performance and Financial Metrics - Refractive surgery revenue was 239 million CNY in 2023, projected to decrease to 218 million CNY in 2024, a decline of 9.08%, but expected to recover to 135 million CNY in the first half of 2025, a growth of 3.26% [4][5] - Vision care revenue was 387 million CNY in 2023, expected to drop to 365 million CNY in 2024, a decrease of 5.82%, with a projected revenue of 169 million CNY in the first half of 2025, a decline of 4.95% [4][5] - Cataract surgery revenue is forecasted to be 157 million CNY in 2024, down 23.61% year-on-year, with 7.66 million CNY in the first half of 2025, a decrease of 17.67% [6] Group 3: Business Model and Franchise Development - The company employs a light-asset, replicable franchise model for vision care centers, providing brand authorization, standardized operations, and supply chain support [4] - In the first half of 2025, 23 new vision care stores were signed, bringing the total to 53 [5] Group 4: Competitive Landscape and Market Position - The Liaoning eye care market is evolving with increased competition from public institutions and private chains, necessitating a focus on technical and service excellence [7][8] - The company is enhancing its service offerings through a "365 myopia prevention system" and digital health management initiatives [8] Group 5: International Expansion and Investment - The acquisition of 70.65% of Japan's Medical Pathway is a strategic move to integrate advanced regenerative medical technologies and enhance the company's competitive edge in global markets [8] - The investment aims to leverage collaborations with top universities and enhance research and clinical capabilities [8]

经济观察网 普瑞眼科2025年业绩预告显示营收预计27.5亿至28.5亿元，净利润亏损5000万至6900万元， 较上年亏损有所收窄。年度报告正式披露后将提供详细财务数据。 业绩经营情况 公司预计2025年度营业收入为27.5亿元至28.5亿元，归属于上市公司股东的净利润亏损5000万元至6900 万元，较2024年亏损额有所收窄。年度报告的正式披露将提供详细财务数据及业务说明。 公司项目推进 公司自2023年以来持续推进"全国连锁化+同城一体化"扩张战略，新开设的十余家眼科医疗机构仍处于 市场培育期。这些新院产生的固定资产折旧、人员薪酬等刚性开支较大，对整体利润形成阶段性压力。 随着营业收入逐步爬升，其规模效应能否驱动亏损进一步收窄值得关注。 业务与技术发展 普瑞眼科在2025年作为全国首批机构引进了卡尔蔡司新一代全飞秒SMILE Pro技术，用于屈光手术，并 重点推广飞秒激光辅助白内障手术等高端解决方案。这些技术引进旨在优化屈光和白内障项目的业务结 构，提升平均客单价。 行业政策与环境 国家组织的人工晶体带量采购政策已在2025年全面执行，叠加医保支付方式改革，对公司白内障项目的 收入和利润空间构成结构性 ...

来源：中国日报网 可是，这双见证过祖国山河变迁的眼睛，却被蒙上了一层白翳。儿女的容颜、窗外的风景，都渐渐褪色 成朦胧的影子，变成了眼前始终挥之不去的"薄纱"。 "以前我还能看电视，和那些做伴的阿婆讲古，现在女儿带着乖孙回家在我面前走来走去，我都看不清 他们的脸。"阿婆谈到这个，语气里满是无奈，"看不见东西只能听声音，吃穿也要人帮忙，有时候想 着，就这样糊涂着走到头算了。" 随着年龄增大，阿婆的病情逐渐加重，视力已下降到几乎不可见，仅保有光感，生活质量严重下降。 子女们看在眼里、急在心里，最终，阿婆在子女们的"连哄带劝"下，终于鼓足勇气走进医院，盼着能在 新春到来之际，重见光明，不留遗憾。 护航光明，为阿婆量身打造手术方案 坐在轮椅上的阿婆，由女儿推着缓缓进入泉州爱尔眼科医院诊室。 "阿婆，别紧张，我们先做个检查，看看眼睛的情况。"泉州爱尔眼科医院院长吴松一耐心地与阿婆沟 通，同时为她进行了全面的检查。最终，林阿婆被确诊为双眼老年性白内障及眼底病，且病情已较为严 重，亟需手术治疗。"阿婆年事已高，白内障已经变成黑色，非常硬，眼底情况复杂，手术难度远超常 规病例。"吴松一向家属详细说明了阿婆病情的特殊性。 泉州爱 ...